Free access to the latest research
Welcome to the Obstetrics Resource Centre, with free access to the latest research in the field.
All content is independently selected by the Editors, Professor James O. Drife from Leeds, UK, and Professor Jim Thornton from Nottingham. The Obstetrics Resource Centre provides you with original articles, reviews, selected must-reads, lectures and a congress planner.
From the other journals
Editor’s comment: Prof. Jim Thornton: Misoprostol favoured agent for labour induction
This huge (280 randomised included 48,068 women) and complex, network meta analysis of different prostgalndins for labour induction has concluded that vaginal misoprostol appears to be the most effective drug/route combination, and that oral misoprostol is the drug/route combination with the lowest Caesarean rate.
Editor’s comment: Prof. Jim Thornton: Pre-conception aspirin and preterm birth
The Effects of Aspirin in Gestation and Reproduction (EAGER) trial showed that low dose aspirin started pre-conception does not improve fertility rates or reduce miscarriage. The trial data are now being reanalysed for a number of secondary outcomes. This analysis tested the effect on preterm birth and found no significant effect.
Selected EJOG Papers
Editor’s comment: Prof. James Drife: Pregnancy after placenta accreta
Placenta accreta results in hysterectomy in about 25% of cases, but in the others conservative treatment is successful. If a woman chooses to have another pregnancy, what are the risks? A recent study found a high risk of recurrent placenta accreta and a fourfold increase in risk of postpartum haemorrhage compared to a control group. This study reports similar findings. Nevertheless a history of placenta accreta was not a risk factor for overall perinatal mortality and was associated with a lower risk of hypertensive disorder in subsequent pregnancy.
A prior placenta accreta is an independent risk factor for post-partum hemorrhage in subsequent gestations
Adi Vinograd, Tamar Wainstock, Moshe Mazor, Salvatore Andrea Mastrolia, Ruthy Beer-Weisel, Vered Klaitman, Doron Dukler, Batel Hamou, Neta Benshalom-Tirosh, Ofir Vinograd, Offer Erez
European Journal of Obstetrics & Gynecology and Reproductive Biology, pages 20 - 24
Editor’s comment: Prof. James Drife: Adjuvanted vaccines in pregnancy: are they safe?
Pregnant women were one of the high-risk groups for whom vaccination was recommended in the “swine flu” pandemic of 2009. The vaccine used in The Netherlands contained an adjuvant to boost the immune response. Information on its safety was limited to showing a lack of teratogenesis, but the immune response affects placentation throughout pregnancy. This case-control study of pre-eclampsia and intra-uterine growth restriction in 2010 provides reassurance that neither condition was associated with the adjuvanted vaccine.
Adjuvanted vaccines in pregnancy: no evidence for effect of the adjuvanted H1N1/09 vaccination on occurrence of preeclampsia or intra-uterine growth restriction
Alies Coenders, Nienke K. Koopmans, Kim Broekhuijsen, Henk Groen, Janna M.A. Karstenberg-Kramer, Kim van Goor, Mariette Groenewout, Aren J. van Loon, Marijke M. Faas, Maria G. van Pampus
European Journal of Obstetrics & Gynecology and Reproductive Biology, pages 14 - 19
Editor’s comment: Prof. James Drife: Off-label prescribing in pregnancy: time for action
Pharmaceutical companies may be reluctant to apply for a product to be licensed for use in pregnancy. This has two results. Effective medications are now being prescribed “off-label”, and women are being denied optimal treatment because some doctors are apprehensive about prescribing it. This important Editorial calls for urgent action on this long-standing problem. Professional societies have an important role, and the Editorial is accompanied by a review from the French College on the off-label use of misoprostol in obstetrics and gynecology.
Luke E. Grzeskowiak, Ben W. Mol
European Journal of Obstetrics & Gynecology and Reproductive Biology, pages 78 - 79